Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck KGaA and Quintiles Announce Innovative Clinical Development Partnership

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Agreement creates unique strategic collaboration for development and clinical trial execution.

Merck KGaA of Darmstadt, Germany, and Quintiles have announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company or division and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well aligned clinical development engine.

In a novel approach to clinical development that is founded on a shared commitment to cost-disciplined science, the collaboration is intended to optimize productivity in the design and execution of studies with a focus on quality, speed and efficiency.

Under this agreement, Merck KGaA will shape and lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution.

Quintiles also will be a key contributor to Merck KGaA’s future clinical trial design activities. In this capacity, Quintiles will focus on delivering superior performance based on optimized clinical trial design and execution strategies, using highly efficient processes and proven technologies.

To fully leverage the expertise of both organizations, leaders from Quintiles will collaborate in strategic decision-making processes affecting the development of the portfolio of Merck KGaA’s prescription medicines division.

“By combining the strengths of Merck KGaA and Quintiles, we are creating a new model in clinical development that will unlock the knowledge and insights of both companies,” says Annalisa Jenkins, Executive Vice President and Head of Global Development and Medical at the division.

Jenkins continued, “This is an innovative and unique collaboration that will help to translate the highest-quality science into efficiency and agility throughout our clinical trials, while enhancing our competitive position in an increasingly challenging environment of clinical drug development.”

Moving forward, Quintiles will be the sole-primary provider of Merck KGaA’s outsourced clinical development services for its global clinical programs.

The agreement will span the full spectrum of clinical development, from Phase I through to post-marketing approvals.

Importantly, it will also allow the Merck KGaA division to expand its reach globally by leveraging the broad local expertise of Quintiles to implement development programs around the world.

“This agreement is built upon a long-standing commitment to trust and transparency between our two organizations, and I’m confident it will only be enhanced by this innovative relationship,” says Tom Pike, Chief Executive Officer at Quintiles.

Pike continued, “We are excited about the opportunities this collaboration provides as we work with Merck KGaA in a new and innovative manner that leverages the best of our combined capabilities. We view this as a key step forward not only for our two companies, but for the way the industry approaches the development of new therapies for the patients we ultimately serve.”

The agreement reflects a shared commitment between both organizations to delivering optimal performance in clinical development.

The objective is to expedite the delivery of new therapeutic options to patients with high medical need across the Merck KGaA division’s core research areas of neurology, oncology, immuno-oncology and immunology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Serono and Intrexon Announce Agreement
Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates.
Thursday, April 02, 2015
Merck Serono Appoints Luciano Rossetti
Appointment of Rossetti as Executive Vice President and Global Head of Research & Development.
Thursday, July 17, 2014
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!